On May 7, Genting Xinyao announced that the Macau Special Administrative Region Drug Administration has officially approved the marketing license application for VELSIPITY (etrasimod) as a new drug for the treatment of adults with moderate to severe active ulcerative colitis. Itramod was approved for marketing as a new drug in the US and the European Union in October of last year and February of this year. Luo Yongqing, CEO of Genting Xinyao, said that the company plans to submit a new drug marketing application for itramod in mainland China this year.
云顶新耀：伊曲莫德新药上市申请在澳门获得批准
Genting Xinyao: Itramod's new drug marketing application approved in Macau
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.